# Mnemo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mnemo-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.mnemo-tx.com
- Total disclosed funding: $63M
- Latest round: Series A (Feb 27, 2021)
- Investors on record: 5

## About

Founded in 2019 and based in Paris, France, Mnemo Therapeutics is a biotechnology company that focuses on the development of cell therapies. The firm was founded by Alain Maiore and has raised EUR 75 million in Series A funding in June 2021.

Mnemo Therapeutics uses the EnfiniT platform, a drug discovery engine that integrates cell therapy through the identification of antigens classes.

Mnemo Therapeutics plans to use its Series A funding to accelerate the development of its platform and chimeric antigen receptors (CAR) T cell therapy platform combining research from Institut Curie and Memorial Sloan Kettering Cancer Center (MSK).

## Funding rounds

- Series A, Feb 27, 2021, $60M — Sofinnova Partners, Alexandria Venture Investments, Redmile Group, Casdin Capital, Emerson Collective
- Seed, Mar 16, 2019, $2.3M — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- Emerson Collective — Series A